Key points are not available for this paper at this time.
Objective Talquetamab is the first-in-class GPRC5DxCD3 bispecific antibody for relapsed/refractory multiple myeloma. Given limited real-world data, this study was conducted with US healthcare providers (HCPs) to understand real-world talquetamab dosing and symptom management.
Building similarity graph...
Analyzing shared references across papers
Loading...
Carolina Schinke
Binod Dhakal
Sandra Mazzoni
Current Medical Research and Opinion
University of California, San Francisco
Emory University
The University of Texas MD Anderson Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Schinke et al. (Fri,) studied this question.
www.synapsesocial.com/papers/68e5b277b6db64358754b35a — DOI: https://doi.org/10.1080/03007995.2024.2387183